Psoriasis

The first patient has been enrolled in a phase 2b study oral orismilast for the treatment of moderate to severe psoriasis, Union therapeutics A/S announced in a press release.

The last time we had a new mechanism of action approved for topical use in psoriasis the movie “Titanic” was setting box office records and we were cranking Chumbawamba on our Sony Discmans. The year was 1997 and the drug was tazarotene gel.

Topical steroids have remained a mainstay first-line treatment for psoriasis, but two new drugs in development aim to revolutionize how topical drugs are used in treatment of the disease.

The FDA has accepted a new drug application for roflumilast cream, Arcutis announced in a press release.

A university psoriatic arthritis center focusing on close collaboration between rheumatologists and dermatologists helped significantly decrease time to diagnosis, according to data published in BMC Rheumatology.

World Psoriasis Day, celebrated on Oct. 29, aims to spread information and build awareness of psoriasis and psoriatic arthritis.

Patients with psoriasis who use biologics are more likely to develop psoriatic arthritis than those on other or no therapies, according to retrospective data published in the Annals of the Rheumatic Diseases.

Abatacept treatment after ustekinumab withdrawal did not prevent psoriasis relapse, according to a randomized clinical trial.

Diagnoses of arthritis, axial symptoms and tendonitis or enthesitis often increase over time before a patient is finally diagnosed with psoriatic arthritis, according to data published in Arthritis Research & Therapy.

In this issue’s cover story, experts discussed how reducing psoriasis in the patient is the best way to curb the negative impact on mental health that stems from disease stigma.